Martin L Sos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3768759/publications.pdf

Version: 2024-02-01

55 papers	12,134 citations	94433 37 h-index	155660 55 g-index
56 all docs	56 docs citations	56 times ranked	18577 citing authors

#	Article	IF	Citations
1	Report of the First International Symposium on NUT Carcinoma. Clinical Cancer Research, 2022, 28, 2493-2505.	7.0	23
2	CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. Molecular Cancer Therapeutics, 2022, 21, 821-830.	4.1	4
3	Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 6643-6655.	6.4	12
4	The next tier of EGFR resistance mutations in lung cancer. Oncogene, 2021, 40, 1-11.	5.9	77
5	Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. Nature Communications, 2021, 12, 2048.	12.8	66
6	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nature Communications, 2021, 12, 5505.	12.8	30
7	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. Npj Precision Oncology, 2021, 5, 102.	5.4	11
8	Sorafenib and everolimus in patients with advanced solid tumors and KRASâ€mutated NSCLC: A phase I trial with early pharmacodynamic FDGâ€PET assessment. Cancer Medicine, 2020, 9, 4991-5007.	2.8	14
9	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of Thoracic Oncology, 2020, 15, 520-540.	1.1	119
10	MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Communications, 2019, 10, 3485.	12.8	54
11	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	17
12	K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. Journal of Thoracic Oncology, 2019, 14, 606-616.	1.1	178
13	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clinical Cancer Research, 2018, 24, 1337-1343.	7.0	71
14	Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. JCO Precision Oncology, 2018, 2, 1-6.	3.0	2
15	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018, 9, 4655.	12.8	107
16	MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell, 2017, 31, 270-285.	16.8	406
17	Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer. Clinical Cancer Research, 2017, 23, 5527-5536.	7.0	44
18	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Science Translational Medicine, 2017, 9, .	12.4	55

#	Article	IF	Citations
19	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports, 2017, 20, 2833-2845.	6.4	40
20	Family matters: How MYC family oncogenes impact small cell lung cancer. Cell Cycle, 2017, 16, 1489-1498.	2.6	75
21	Resistance Mechanisms to AZD9291 and Rociletinibâ€"Response. Clinical Cancer Research, 2017, 23, 3967-3968.	7.0	3
22	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clinical Cancer Research, 2016, 22, 4837-4847.	7.0	223
23	Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. Journal of Thoracic Oncology, 2015, 10, 1049-1057.	1.1	85
24	Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. Journal of Thoracic Oncology, 2015, 10, e40-e43.	1.1	33
25	Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics. Clinical Cancer Research, 2015, 21, 2236-2243.	7.0	147
26	Discovery and functional characterization of a neomorphic PTEN mutation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13976-13981.	7.1	38
27	Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. Journal of Medicinal Chemistry, 2015, 58, 6844-6863.	6.4	92
28	Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors. Cell Reports, 2014, 8, 1037-1048.	6.4	69
29	Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design. Journal of Medicinal Chemistry, 2013, 56, 5757-5772.	6.4	17
30	A Neo-Substrate that Amplifies Catalytic Activity of Parkinsonâ€™s-Disease-Related Kinase PINK1. Cell, 2013, 154, 737-747.	28.9	229
31	K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature, 2013, 503, 548-551.	27.8	1,713
32	Characteristics of Lung Cancers Harboring NRAS Mutations. Clinical Cancer Research, 2013, 19, 2584-2591.	7.0	134
33	Staurosporine-Derived Inhibitors Broaden the Scope of Analog-Sensitive Kinase Technology. Journal of the American Chemical Society, 2013, 135, 18153-18159.	13.7	31
34	Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants. Clinical Cancer Research, 2012, 18, 4682-4690.	7.0	252
35	Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Modern Pathology, 2012, 25, 1473-1480.	5.5	118
36	A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17034-17039.	7.1	167

#	Article	IF	Citations
37	AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. EMBO Journal, 2012, 31, 3961-3975.	7.8	53
38	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110.	21.4	1,186
39	Optimization of Dosing for EGFR-Mutant Nonâ€“Small Cell Lung Cancer with Evolutionary Cancer Modeling. Science Translational Medicine, 2011, 3, 90ra59.	12.4	457
40	Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery, 2011, 1, 78-89.	9.4	455
41	Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. Bioorganic and Medicinal Chemistry, 2011, 19, 429-439.	3.0	10
42	ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors. Clinical Cancer Research, 2011, 17, 7394-7401.	7.0	179
43	A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Medicine, 2011, 17, 1504-1508.	30.7	224
44	Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer. Science Translational Medicine, 2010, 2, 62ra93.	12.4	761
45	Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation. Cancer Research, 2010, 70, 868-874.	0.9	191
46	Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2010, 53, 2892-2901.	6.4	54
47	Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling. PLoS ONE, 2010, 5, e8919.	2.5	24
48	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18351-18356.	7.1	251
49	Systematically linking drug susceptibility to cancer genome aberrations. Cell Cycle, 2009, 8, 3652-3656.	2.6	3
50	PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. Cancer Research, 2009, 69, 3256-3261.	0.9	480
51	Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 2009, 462, 108-112.	27.8	2,707
52	Predicting drug susceptibility of nonâ€“small cell lung cancers based on genetic lesions. Journal of Clinical Investigation, 2009, 119, 1727-1740.	8.2	230
53	Expression of Signaling Mediators Downstream of EGF-Receptor Predict Sensitivity to Small Molecule Inhibitors Directed Against the EGF-Receptor Pathway. Journal of Thoracic Oncology, 2008, 3, 170-173.	1.1	13
54	Early Detection of Erlotinib Treatment Response in NSCLC by 3â€²-Deoxy-3â€²-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET). PLoS ONE, 2008, 3, e3908.	2.5	80

#	Article	IF	Citations
55	Inhibition of Nuclear Translocation of Nuclear Factor-Î¹B Despite Lack of Functional ÎĪ¹BÎ± Protein Overcomes Multiple Defects in Apoptosis Signaling in Human B-Cell Malignancies. Clinical Cancer Research, 2005, 11, 8186-8194.	7.0	19